International Clinical Trials Day marked
20 May 2015
Melinda Paton would not be alive today without MIA. Over three years ago, Melinda was told she had only nine months to live due to her stage four melanoma diagnosis. After being transferred to MIA she was placed on an Anti-PD-1 clinical trial.
"I started the Anti-PD-1 trial in September and by December 2013; my tumour had gone from the bowel. When I saw the scan, I was in complete disbelief; I couldn’t believe that it had just disappeared,” says Melinda.
“When I first met with Dr Georgina Long, as a stage 4 patient, the tumour was causing me a lot of pain and I was very weak. The tumours were progressing very quickly and I had surgery in December to have a lymph node removed. After this is when I went onto PD-1, where I noticed a difference almost immediately.
“With PD-1, I don’t have any pain, I’m not tired, and I don’t feel sick. I work full time and it lets me live as normal life as possible. The access to these drugs has been lifesaving, without them there is no doubt I would have died a long time ago.”
Melinda is benefiting from Anti-PD1 immunotherapy treatments and she is able to live as normal life as possible. It is thanks to dedicated clinicians that have discovered these clinical trials that are saving patients lives and improving cancer care globally.
There is still more work to be done. Donate now.
“I had a complete response within about six months. All of my tumours disappeared."
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.